{
    "nctId": "NCT01017549",
    "briefTitle": "Post Market Study Using the Xoft Axxent System",
    "officialTitle": "Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent\u00ae Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Number of Participants With Delivery of 34 Gy in 10 Fractions",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>50 years\n* Tumor with Tis, T1, N0, M0 - (AJC Classification)\n* Invasive ductal carcinoma or ductal carcinoma in situ\n* Negative microscopic surgical margins of at least 1mm in all directions\n* Adequate skin spacing between balloon surface and surface of the skin - (\\> 7mm)\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding - (During the treatment portion of the study, sexually active women of childbearing age will be asked to use pregnancy prevention)\n* Scleroderma, systemic sclerosis and active lupus\n* Infiltrating lobular histology",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}